THE EFFECT OF LIVER-DISEASE AND FOOD ON PLASMA MEGX CONCENTRATIONS

被引:12
作者
PRITCHARDDAVIES, R [1 ]
GROSS, AS [1 ]
SHENFIELD, GM [1 ]
机构
[1] ROYAL N SHORE HOSP,DEPT CLIN PHARMACOL,ST LEONARDS,NSW 2065,AUSTRALIA
关键词
LIVER FUNCTION; LIGNOCAINE (LIDOCAINE); MONOETHYLGLYCINEXYLIDIDE; (MEGX); FOOD;
D O I
10.1111/j.1365-2125.1994.tb04279.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Plasma monoethylglycinexylidide (MEGX) concentrations were measured in 15 healthy controls (age 23-46 years) and 12 patients with biopsy proven cirrhosis (age 34-70 years) 30 min after 1 mg kg(-1) intravenous lignocaine. Mean (+/- s.d.) MEGX concentrations were 57 +/- 33 ng ml(-1) in the controls compared with 21 +/- 18 ng ml(-1) in the cirrhotics (P < 0.05), but there was overlap in the range of concentrations. MEGX concentrations were inversely correlated with age, but not disease severity, in the cirrhotic patients (r = 0.62, P = 0.04) but not in the control subjects. In a second study 20 healthy subjects were given 1 mg kg(-1) intravenous lignocaine on two occasions; either fed or fasted, and samples taken at 15, 30 and 60 min after dosage. MEGX concentrations were not significantly different at any time within either day or between fed and fasted study days. There was no correlation with age. The plasma lignocaine concentration at 15 min was significantly higher fed than fasted (2.88 +/- 2.44 and 1.82 +/- 0.96 mu g ml(-1), P = 0.01). Measurement of plasma MEGX after i.v. lignocaine is a useful test of liver function and may be performed in fed or fasted subjects. It is reproducible within an individual but is not specific for cirrhosis and appears age-related in liver disease.
引用
收藏
页码:298 / 301
页数:4
相关论文
共 15 条
[1]   LIDOCAINE METABOLISM IN HUMAN-LIVER MICROSOMES BY CYTOCHROME-P450IIIA4 [J].
BARGETZI, MJ ;
AOYAMA, T ;
GONZALEZ, FJ ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (05) :521-527
[2]  
CHEN Y, 1992, CLIN EXP PHARM PHY S, V21, P13
[3]   EFFECT OF FOOD ON LIDOCAINE KINETICS - MECHANISM OF FOOD-RELATED ALTERATION IN HIGH INTRINSIC CLEARANCE DRUG ELIMINATION [J].
ELVIN, AT ;
COLE, AFD ;
PIEPER, JA ;
ROLBIN, SH ;
LALKA, D .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (04) :455-460
[4]   ANTIPYRINE, PARACETAMOL, AND LIGNOCAINE ELIMINATION IN CHRONIC LIVER-DISEASE [J].
FORREST, JAH ;
FINLAYSON, NDC ;
ADJEPONYAMOAH, KK ;
PRESCOTT, LF .
BRITISH MEDICAL JOURNAL, 1977, 1 (6073) :1384-1387
[5]  
KEENAGHAN J B, 1972, Journal of Pharmacology and Experimental Therapeutics, V180, P454
[6]   CYCLOSPORINE METABOLISM IN HUMAN-LIVER - IDENTIFICATION OF A CYTOCHROME-P-450III GENE FAMILY AS THE MAJOR CYCLOSPORINE-METABOLIZING ENZYME EXPLAINS INTERACTIONS OF CYCLOSPORINE WITH OTHER DRUGS [J].
KRONBACH, T ;
FISCHER, V ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (06) :630-635
[7]  
OELLERICH M, 1989, LANCET, V1, P640
[8]  
OELLERICH M, 1987, J CLIN CHEM CLIN BIO, V25, P845
[9]   LIDOCAINE METABOLITE FORMATION AS A MEASURE OF LIVER-FUNCTION IN PATIENTS WITH CIRRHOSIS [J].
OELLERICH, M ;
BURDELSKI, M ;
LAUTZ, HU ;
SCHULZ, M ;
SCHMIDT, FW ;
HERRMANN, H .
THERAPEUTIC DRUG MONITORING, 1990, 12 (03) :219-226
[10]  
POTTER JM, 1992, TRANSPLANT P, V24, P198